Like Bio-Hermes-001, the Bio-Hermes-002 study is paving the way for improving participation by trial participants who are traditionally underrepresented in Alzheimer’s clinical research, with an ...

Among a number of strategies toward this goal, tissue engineering and regenerative medicine (TERM) has gradually evolved into a promising approach to meet future needs of patients. TERM has recently ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with so-called “HER2-ultralow” status. The company’s PATHWAY HER2 ...

“One in eight women in the United States will face invasive breast cancer in their lifetime,” said Matt Sause, CEO of Roche Diagnostics, in a press release. “The rising incidence of metastatic breast ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

“One in eight women in the United States will face invasive breast cancer in their lifetime,” said Matt Sause, CEO of Roche Diagnostics ... of HER2 receptor protein expressed in breast cancer tissue ...

With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics ... protein expressed in breast cancer tissue samples. The PATHWAY HER2 ...

With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics, helping to expand patient ... the level of HER2 receptor protein expressed in ...

CRISPR technology has revolutionized genetic testing and disease detection, offering precise, rapid, and cost-effective diagnostic solutions. This gene-editing tool has been adapted for molecular ...